ClinicalTrials.gg
CompletedNCT03423173Updated Oct 20, 2020Results posted

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

A Phase 3 interventional study of TAK-003 and Placebo in Dengue Fever, sponsored by Takeda. Completed at 14 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-20.

Sponsored by Takeda · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
923
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Dengue by Takeda — 2 open to participants now, 5 under way, 3 of them phase 3. Dengue · Takeda.

Enrollment
3rd of 15
923 · median 400
Started
2018
with 2 others
Phase 3
9 of 17
1 open now
Registered
7th of 17
by date

Among the 17 studies in Dengue by Takeda, this one is the 3rd largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2018, is one of 9 in phase 3, and was the 7th registered.

Dengue

283 studies on the registry are indexed under Dengue; 44 are open to participants now.

Browse Dengue studies →

Open to participants now

2 of the 17 studies in Dengue by Takeda are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Dengue by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive TDV lots in healthy participants aged 18 to 60 years in non-endemic country(ies) for dengue.

Read the detailed description

The vaccine tested in this study is Takeda's Tetravalent Dengue Vaccine Candidate (TDV). The primary objective of this trial is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive lots of TDV in healthy participants in non-endemic country(ies) for dengue.

The study will enroll approximately 924 healthy participants. Participants will be randomized in 2:2:2:1 to one of 4 trial groups to receive TDV (Lots 1, 2 or 3) or placebo:

  • TDV 0.5 mL subcutaneous injection OR
  • Placebo normal saline solution (0.9% NaCl) for injection.

In each trial group, all participants will receive 2 doses of TDV or placebo by subcutaneous injection on Days 1 (Month 0) and 90 (Month 3). Immunogenicity will be assessed in participants included in the immunogenicity subset (TDV groups: 176 participants each and placebo group: 88 participants) and safety will be assessed in all participants in each group.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 270 days. Participants will make multiple visits to the clinic including a final visit at Day 270.

03

Conditions studied

  • Dengue Fever

Browse trials for

Keywords

  • Vaccine
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and the clinical judgment of the Investigator.
  2. Signs and dates a written form and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements.

Exclusion criteria

Exclusion Criteria:

  1. Has an elevated oral temperature (≥38°C or 100.4°F) within 3 days of the intended date of vaccination.
  2. Known or allergy to any of the vaccine components (including of the vaccine or placebo).
  3. Has any history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (e.g., Guillain-Barré syndrome).
  4. Known or suspected impairment/alteration of immune function, including:

    1. Chronic use of oral (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (M0) (use of inhaled, intranasal, or topical corticosteroids is allowed)
    2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥ 2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (M0).
    3. Administration of immunoglobulins and/or any blood products within the 3 months prior to Day 1 (M0) or planned administration during the trial.
    4. Receipt of immunostimulants within 60 days prior to Day 1 (M0).
    5. virus infection.
    6. Genetic immunodeficiency.
  5. Has abnormalities of splenic or thymic function.
  6. Has a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
  7. Has any serious chronic or progressive disease according to judgment of the Investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).
  8. Has (BMI) greater than or equal to 35 kg/m\^2 (= weight in kg/[height in meters\^2]).
  9. Has history of substance or alcohol abuse within the past 2 years.
  10. Had previous and planned vaccination (during the trial conduct) against any flavivirus including dengue, yellow fever (YF), Japanese encephalitis (JE) viruses or tick-borne encephalitis.
  11. Has a current or previous infection with a flavivirus such as dengue, Zika, YF, JE, West Nile (WN) fever, tick-borne encephalitis or Murray Valley encephalitis and participants with a history of prolonged (≥1 year) habitation in a dengue endemic area.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
923 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    TDV placebo matching injection, subcutaneously (SC) once on Day 1, and Day 90.

    Biological: Placebo

  • Experimental
    TDV Lot 1

    Participants were administered TDV lot 1, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.

    Biological: TAK-003

  • Experimental
    TDV Lot 2

    Participants were administered TDV lot 2, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.

    Biological: TAK-003

  • Experimental
    TDV Lot 3

    Participants were administered TDV lot 3, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection once on Day 1, and Day 90.

    Biological: TAK-003

Interventions

  • BiologicalTAK-003

    TDV subcutaneous injection

    Also known as: TDV

  • BiologicalPlacebo

    TDV Placebo-matching normal saline (0.9% NaCl) subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 in the Immunogenicity Subset

    GMTs of neutralizing antibodies for each of the 4 Dengue Serotypes was measured by microneutralization test 50% \[MNT50\]. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.

    Time frame: 1 month post second dose (Day 120)

Secondary outcomes

  1. Percentage of Participants Who Are Seropositive for Each of the 4 Dengue Serotypes at Days 120 and 270 in the Immunogenicity Subset

    Seropositivity was defined as a reciprocal neutralizing titer ≥ 10. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.

    Time frame: 1 month post second dose (Day 120) and 6 months post second dose (Day 270)

  2. GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270 in the Immunogenicity Subset

    GMTs of neutralizing antibodies for each of the 4 Dengue Serotypes was measured by microneutralization test 50% \[MNT50\]. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.

    Time frame: 6 months post second dose (Day 270)

  3. Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity After Each Vaccination

    Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents daily activity with or without treatment), redness (erythema) (\<25 mm, mild: \>25 - ≤50 mm, moderate: \>50 - ≤100 mm, severe: \>100 mm) and swelling (edema/induration) (\<25 mm, mild: \>25 - ≤50 mm, moderate: \>50 - ≤100 mm, severe: \>100 mm ). The percentages were rounded off to the first decimal place.

    Time frame: Within 7 Days of each Vaccination (day of vaccination + 6 days)

  4. Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity After Each Vaccination

    Solicited systemic AEs include fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination. Solicited systemic AEs (headache, asthenia, malaise and myalgia) was graded from 0 to 3 by severity; where 0=None, 1=Mild: No interference with daily activity, 2=Moderate: Interference with daily activity, 3=Severe: Prevents daily activity; A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 14 days after vaccination. Fever was excluded from the overall count as no severity grading was applied for it. The percentages were rounded off to the first decimal place.

    Time frame: Within 14 Days of each Vaccination (day of vaccination + 13 days)

  5. Percentage of Participants With Any Unsolicited Adverse Events (AEs) After Each Vaccination

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.

    Time frame: Within 28 days (day of vaccination + 27 days) after each vaccination

  6. Percentage of Participants With Serious Adverse Events (SAEs)

    An SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event that may require intervention to prevent any of the above mentioned criteria and/or may expose the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization. The percentages were rounded off to the first decimal place.

    Time frame: From the first vaccination on Day 1 until the end of the trial (Day 270)

  7. Percentage of Participants With Medically Attended Adverse Events (MAAEs)

    MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria. The percentages were rounded off to the first decimal place.

    Time frame: From the first vaccination on Day 1 until the end of the trial (Day 270)

07

Results

Posted Oct 20, 2020

Participant flow

Participants took part in the study at 14 investigative sites in the United States from 12 February 2018 to 14 January 2019.

Participant flow — Overall Study
MilestonePlaceboTDV Lot 1TDV Lot 2TDV Lot 3
Started132263264264
Received at least 1 dose of the ip131263262263
Completed113228237234
Not completed19352730
Withdrew: Randomized but not vaccinated1021
Withdrew: Adverse event1111
Withdrew: Lost to follow-up10191722
Withdrew: Withdrawal of consent41045
Withdrew: Death1000
Withdrew: Reason not specified2531

Outcome measures

PrimaryGeometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 in the Immunogenicity Subset

GMTs of neutralizing antibodies for each of the 4 Dengue Serotypes was measured by microneutralization test 50% \[MNT50\]. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.

Time frame:
1 month post second dose (Day 120)
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 in the Immunogenicity Subset
titerPlaceboTDV Lot 1TDV Lot 2TDV Lot 3
DENV-15.3 (4.7 to 6.1)202.9 (155.9 to 264.1)293.8 (214.9 to 401.6)322.1 (238.1 to 435.9)
DENV-26.3 (4.8 to 8.2)3090.3 (2494.8 to 3828.0)2386.0 (1913.0 to 2976.1)3574.1 (3087.8 to 4137.0)
DENV-35.4 (4.6 to 6.3)149.5 (116.6 to 191.6)117.3 (92.7 to 148.4)122.8 (97.4 to 155.0)
DENV-45.4 (4.7 to 6.2)116.3 (93.8 to 144.2)187.9 (154.4 to 228.6)115.8 (94.0 to 142.5)
Statistical analysis
  • TDV Lot 1 vs TDV Lot 2 · Geometric mean titer (gmt) ratio: 0.69 · 95% CI 0.46 to 1.04Analysis of variance (ANOVA) model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 2 vs TDV Lot 3 · Gmt ratio: 0.91 · 95% CI 0.60 to 1.38ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 3 · Gmt ratio: 0.63 · 95% CI 0.41 to 0.96ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 2 · Gmt ratio: 1.30 · 95% CI 0.98 to 1.71ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 2 vs TDV Lot 3 · Gmt ratio: 0.67 · 95% CI 0.51 to 0.88ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 3 · Gmt ratio: 0.86 · 95% CI 0.65 to 1.15ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 2 · Gmt ratio: 1.27 · 95% CI 0.91 to 1.78ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 2 vs TDV Lot 3 · Gmt ratio: 0.95 · 95% CI 0.68 to 1.33ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 3 · Gmt ratio: 1.22 · 95% CI 0.87 to 1.71ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 2 · Gmt ratio: 0.62 · 95% CI 0.46 to 0.82ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 2 vs TDV Lot 3 · Gmt ratio: 1.62 · 95% CI 1.22 to 2.17ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 3 · Gmt ratio: 1.00 · 95% CI 0.75 to 1.35ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
SecondaryPercentage of Participants Who Are Seropositive for Each of the 4 Dengue Serotypes at Days 120 and 270 in the Immunogenicity Subset

Seropositivity was defined as a reciprocal neutralizing titer ≥ 10. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.

Time frame:
1 month post second dose (Day 120) and 6 months post second dose (Day 270)
Reported as:
Number · percentage of participants
Percentage of Participants Who Are Seropositive for Each of the 4 Dengue Serotypes at Days 120 and 270 in the Immunogenicity Subset
percentage of participantsPlaceboTDV Lot 1TDV Lot 2TDV Lot 3
DENV-1, Day 1201.7 (0.0 to 8.9)97.5 (92.9 to 99.5)96.9 (92.3 to 99.1)99.2 (95.4 to 100.0)
DENV-2, Day 1206.7 (1.8 to 16.2)99.2 (95.4 to 100.0)98.4 (94.5 to 99.8)100.0 (96.9 to 100.0)
DENV-3, Day 1201.7 (0.0 to 8.9)97.5 (92.9 to 99.5)94.6 (89.1 to 97.8)98.3 (94.0 to 99.8)
DENV-4, Day 1201.7 (0.0 to 8.9)97.5 (92.9 to 99.5)100.0 (97.2 to 100.0)97.5 (92.7 to 99.5)
DENV-1, Day 2703.4 (0.4 to 11.7)97.3 (92.3 to 99.4)89.4 (82.6 to 94.3)95.8 (90.5 to 98.6)
DENV-2, Day 2706.8 (1.9 to 16.5)100.0 (96.7 to 100.0)97.6 (93.1 to 99.5)99.2 (95.4 to 100.0)
DENV-3, Day 2700 (0.0 to 6.1)95.5 (89.8 to 98.5)88.7 (81.8 to 93.7)92.5 (86.2 to 96.5)
DENV-4, Day 2700 (0.0 to 6.1)92.8 (86.3 to 96.8)94.3 (88.6 to 97.7)91.7 (85.2 to 95.9)
Statistical analysis
  • TDV Lot 1 vs TDV Lot 2 · Seropositivity rates difference: 0.60 · 95% CI -4.99 to 6.0695% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 3 · Seropositivity rate difference: -1.65 · 95% CI -6.90 to 3.1995% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 2 vs TDV Lot 3 · Seropositivity rate difference: -2.25 · 95% CI -7.45 to 2.6995% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 2 · Seropositivity rate difference: 7.87 · 95% CI 0.64 to 15.3095% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 3 · Seropositivity rate difference: 1.50 · 95% CI -4.67 to 7.6595% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 2 vs TDV Lot 3 · Seropositivity rate difference: -6.37 · 95% CI -14.00 to 1.0495% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 2 · Seropositivity rate difference: 0.72 · 95% CI -3.87 to 5.2995% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 3 · Seropositivity rate difference: -0.83 · 95% CI -5.24 to 3.1795% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 2 vs TDV Lot 3 · Seropositivity rate difference: -1.55 · 95% CI -6.05 to 2.5895% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 2 · Seropositivity rate difference: 2.42 · 95% CI -2.12 to 7.4495% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 3 · Seropositivity rate difference: 0.83 · 95% CI -3.41 to 5.2495% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 2 vs TDV Lot 3 · Seropositivity rate difference: -1.59 · 95% CI -6.67 to 3.1795% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 2 · Seropositivity rate difference: 2.93 · 95% CI -3.07 to 9.0695% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 3 · Seropositivity rate difference: -0.81 · 95% CI -6.17 to 4.4495% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 2 vs TDV Lot 3 · Seropositivity rate difference: -3.73 · 95% CI -9.74 to 2.0395% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 2 · Seropositivity rate difference: 6.79 · 95% CI -1.03 to 14.5695% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 3 · Seropositivity rate difference: 3.00 · 95% CI -4.28 to 10.2395% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 2 vs TDV Lot 3 · Seropositivity rate difference: -3.79 · 95% CI -11.97 to 4.3995% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 2 · Seropositivity rate difference: -2.50 · 95% CI -7.68 to 1.5595% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 3 · Seropositivity rate difference: 0.04 · 95% CI -5.47 to 5.6295% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 2 vs TDV Lot 3 · Seropositivity rate difference: 2.54 · 95% CI -1.52 to 7.8195% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 2 · Seropositivity rate difference: -1.52 · 95% CI -9.14 to 5.6995% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 1 vs TDV Lot 3 · Seropositivity rate difference: 1.13 · 95% CI -6.90 to 8.9595% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
  • TDV Lot 2 vs TDV Lot 3 · Seropositivity rate difference: 2.64 · 95% CI -4.68 to 10.1895% CI for the differences in seropositivity rates between TDV lots were calculated using the Newcombe and Wilson method.
SecondaryGMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270 in the Immunogenicity Subset

GMTs of neutralizing antibodies for each of the 4 Dengue Serotypes was measured by microneutralization test 50% \[MNT50\]. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.

Time frame:
6 months post second dose (Day 270)
Reported as:
Geometric mean · titer
GMTs of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270 in the Immunogenicity Subset
titerPlaceboTDV Lot 1TDV Lot 2TDV Lot 3
DENV-15.4 (4.9 to 5.9)122.5 (93.0 to 161.3)136.7 (95.2 to 196.3)168.4 (120.8 to 234.8)
DENV-25.8 (5.0 to 6.8)1507.2 (1242.3 to 1828.4)1097.5 (856.9 to 1405.5)1693.3 (1399.9 to 2048.3)
DENV-3NA (NA to NA)88.0 (69.2 to 111.9)63.1 (49.9 to 79.7)71.6 (57.3 to 89.5)
DENV-4NA (NA to NA)64.1 (49.5 to 83.1)77.5 (60.8 to 98.8)51.2 (40.0 to 65.5)
Statistical analysis
  • TDV Lot 1 vs TDV Lot 2 · Gmt ratio: 0.90 · 95% CI 0.56 to 1.42ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 2 vs TDV Lot 3 · Gmt ratio: 0.81 · 95% CI 0.51 to 1.28ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 3 · Gmt ratio: 0.73 · 95% CI 0.46 to 1.16ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 2 · Gmt ratio: 1.37 · 95% CI 1.02 to 1.86ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 2 vs TDV Lot 3 · Gmt ratio: 0.65 · 95% CI 0.48 to 0.87ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 3 · Gmt ratio: 0.89 · 95% CI 0.66 to 1.21ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 2 · Gmt ratio: 1.40 · 95% CI 1.00 to 1.94ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 2 vs TDV Lot 3 · Gmt ratio: 0.88 · 95% CI 0.64 to 1.21ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 3 · Gmt ratio: 1.23 · 95% CI 0.88 to 1.71ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 2 · Gmt ratio: 0.83 · 95% CI 0.58 to 1.18ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 2 vs TDV Lot 3 · Gmt ratio: 1.51 · 95% CI 1.07 to 2.14ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
  • TDV Lot 1 vs TDV Lot 3 · Gmt ratio: 1.25 · 95% CI 0.88 to 1.78ANOVA model was used for analysis, including natural logarithms of titers as a response variable and trial group as a factor.
SecondaryPercentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity After Each Vaccination

Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents daily activity with or without treatment), redness (erythema) (\<25 mm, mild: \>25 - ≤50 mm, moderate: \>50 - ≤100 mm, severe: \>100 mm) and swelling (edema/induration) (\<25 mm, mild: \>25 - ≤50 mm, moderate: \>50 - ≤100 mm, severe: \>100 mm ). The percentages were rounded off to the first decimal place.

Time frame:
Within 7 Days of each Vaccination (day of vaccination + 6 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity After Each Vaccination
percentage of participantsPlaceboTDV Lot 1TDV Lot 2TDV Lot 3
After Vaccination 1, Any Local AE17.551.048.450.0
After Vaccination 1, Pain-Any Severity16.745.540.641.7
After Vaccination 1, Pain-Mild15.039.934.837.7
After Vaccination 1, Pain-Moderate1.75.55.14.0
After Vaccination 1, Pain-Severe000.80
After Vaccination 1, Erythema-Any Severity0.825.720.323.0
After Vaccination 1, Erythema-Mild: 2.5-5(cm)023.718.421.8
After Vaccination 1,Erythema-Moderate: >5-<=10(cm)01.22.00.8
After Vaccination 1, Erythema-Missing Severity0.80.800.4
After Vaccination 1, Swelling-Any Severity0.87.95.56.3
After Vaccination 1, Swelling-Mild: 2.5-5(cm)07.15.15.6
After Vaccination 1,Swelling-Moderate: >5-<=10(cm)00.40.40
After Vaccination 1, Swelling-Missing Severity0.80.400.8
After Vaccination 2, Local AE-Any13.037.942.137.1
After Vaccination 2, Pain-Any Severity13.032.834.630.9
After Vaccination 2, Pain-Mild13.027.630.028.4
After Vaccination 2, Pain-Moderate03.93.82.5
After Vaccination 2, Pain-Severe01.30.80
After Vaccination 2, Erythema-Any Severity019.018.814.3
After Vaccination 2,Erythema-Mild: 2.5-5(cm)018.117.113.1
After Vaccination 2,Erythema-Moderate: >5-<=10(cm)00.41.71.3
After Vaccination 2,Erythema-Missing Severity00.400
After Vaccination 2, Swelling-Any Severity06.94.24.7
After Vaccination 2,Swelling-Mild: 2.5-5(cm)06.54.24.2
After Vaccination 2,Swelling-Moderate: >5-<=10(cm)0000.4
After Vaccination 2,Swelling-Missing Severity00.400
SecondaryPercentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity After Each Vaccination

Solicited systemic AEs include fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination. Solicited systemic AEs (headache, asthenia, malaise and myalgia) was graded from 0 to 3 by severity; where 0=None, 1=Mild: No interference with daily activity, 2=Moderate: Interference with daily activity, 3=Severe: Prevents daily activity; A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 14 days after vaccination. Fever was excluded from the overall count as no severity grading was applied for it. The percentages were rounded off to the first decimal place.

Time frame:
Within 14 Days of each Vaccination (day of vaccination + 13 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity After Each Vaccination
percentage of participantsPlaceboTDV Lot 1TDV Lot 2TDV Lot 3
After Vaccination 1, Systemic AEs-Any34.743.339.542.9
After Vaccination 1, Headache-Any Severity22.528.927.028.6
After Vaccination 1, Headache-Mild17.521.319.921.4
After Vaccination 1, Headache-Moderate4.25.95.56.0
After Vaccination 1, Headache-Severe0.81.61.61.2
After Vaccination 1, Asthenia-Any Severity9.213.115.211.9
After Vaccination 1, Asthenia-Mild7.57.99.46.3
After Vaccination 1, Asthenia-Moderate0.83.64.34.8
After Vaccination 1, Asthenia-Severe0.81.61.60.8
After Vaccination 1, Malaise-Any Severity12.415.514.515.5
After Vaccination 1, Malaise-Mild9.17.17.88.3
After Vaccination 1, Malaise-Moderate2.56.34.75.6
After Vaccination 1, Malaise-Severe0.82.02.01.6
After Vaccination 1, Myalgia-Any Severity15.826.525.422.2
After Vaccination 1, Myalgia-Mild13.319.016.014.3
After Vaccination 1, Myalgia-Moderate2.57.17.87.5
After Vaccination 1, Myalgia-Severe00.41.60.4
After Vaccination 1, Fever-Any Severity1.70.82.42.0
After Vaccination 1, Fever-38.0-<38.50.80.40.81.2
After Vaccination 1, Fever-38.5-<39.000.40.80.8
After Vaccination 1, Fever-39.0-<39.50.800.40
After Vaccination 1, Fever-≥41.0000.40
After Vaccination 2, Systemic AEs-Any23.526.729.228.0
After Vaccination 2, Headache-Any Severity19.118.122.518.6
After Vaccination 2, Headache-Mild15.715.115.813.6
After Vaccination 2, Headache-Moderate3.53.05.44.2
After Vaccination 2, Headache-Severe001.30.8
After Vaccination 2, Asthenia-Any Severity8.79.18.86.0
After Vaccination 2, Asthenia-Mild7.06.06.33.4
After Vaccination 2, Asthenia-Moderate1.73.02.12.1
After Vaccination 2, Asthenia-Severe000.40.4
After Vaccination 2, Malaise-Any Severity7.811.611.37.7
After Vaccination 2, Malaise-Mild5.27.37.54.7
After Vaccination 2, Malaise-Moderate2.64.33.32.1
After Vaccination 2, Malaise-Severe000.40.9
After Vaccination 2, Myalgia-Any Severity7.816.814.614.9
After Vaccination 2, Myalgia-Mild5.212.110.411.9
After Vaccination 2, Myalgia-Moderate2.63.93.32.6
After Vaccination 2, Myalgia-Severe00.90.80.4
After Vaccination 2, Fever-Any Severity1.70.90.82.1
After Vaccination 2, Fever-38.0-<38.51.70.90.40.9
After Vaccination 2, Fever-38.5-<39.0000.40.4
After Vaccination 2, Fever-39.0-<39.50000.4
After Vaccination 2, Fever-39.5-<40.00000.4
SecondaryPercentage of Participants With Any Unsolicited Adverse Events (AEs) After Each Vaccination

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.

Time frame:
Within 28 days (day of vaccination + 27 days) after each vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Any Unsolicited Adverse Events (AEs) After Each Vaccination
percentage of participantsPlaceboTDV Lot 1TDV Lot 2TDV Lot 3
After First Vaccination13.718.618.016.7
After Second Vaccination7.810.57.76.6
SecondaryPercentage of Participants With Serious Adverse Events (SAEs)

An SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event that may require intervention to prevent any of the above mentioned criteria and/or may expose the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization. The percentages were rounded off to the first decimal place.

Time frame:
From the first vaccination on Day 1 until the end of the trial (Day 270)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs)
percentage of participantsPlaceboTDV Lot 1TDV Lot 2TDV Lot 3
Percentage of Participants With Serious Adverse Events (SAEs)3.13.81.11.1
SecondaryPercentage of Participants With Medically Attended Adverse Events (MAAEs)

MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria. The percentages were rounded off to the first decimal place.

Time frame:
From the first vaccination on Day 1 until the end of the trial (Day 270)
Reported as:
Number · percentage of participants
Percentage of Participants With Medically Attended Adverse Events (MAAEs)
percentage of participantsPlaceboTDV Lot 1TDV Lot 2TDV Lot 3
Percentage of Participants With Medically Attended Adverse Events (MAAEs)13.717.812.311.8

Adverse events

Collected over All-cause mortality and Serious adverse events: From the first vaccination on Day 1 until the end of the trial (Day 270); Other adverse events: Up to 28 days (Day of vaccination+27 subsequent days) after each vaccination.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/131 (0.8%)4/131 (3.1%)4/131 (3.1%)
TDV Lot 10/264 (0%)10/264 (3.8%)16/264 (6.1%)
TDV Lot 20/261 (0%)3/261 (1.1%)26/261 (10%)
TDV Lot 30/263 (0%)3/263 (1.1%)23/263 (8.7%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPlaceboTDV Lot 1TDV Lot 2TDV Lot 3
PneumoniaInfections and infestations1/1310/2640/2610/263
SepsisInfections and infestations1/1310/2640/2610/263
HypercalcaemiaMetabolism and nutrition disorders1/1310/2640/2610/263
Lung squamous cell carcinoma stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1310/2640/2610/263
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1310/2640/2610/263
Intracranial aneurysmNervous system disorders1/1310/2640/2610/263
Postmenopausal haemorrhageReproductive system and breast disorders1/1310/2640/2610/263
SciaticaNervous system disorders0/1312/2640/2610/263
Rhegmatogenous retinal detachmentEye disorders0/1310/2641/2610/263
NauseaGastrointestinal disorders0/1310/2641/2610/263
Most frequent other events
Most frequent other events
EventPlaceboTDV Lot 1TDV Lot 2TDV Lot 3
Injection site pruritusGeneral disorders0/1318/26415/2613/263
Injection site bruisingGeneral disorders1/1315/26410/26112/263
Upper respiratory tract infectionInfections and infestations4/1314/2646/2619/263

Baseline characteristics

Randomized Set included all randomized participants irrespective of whether a dose of the trial vaccine (TDV or placebo) was received.

Age, Continuous
Age, Continuous(years)PlaceboTDV Lot 1TDV Lot 2TDV Lot 3Total
Mean40.7 ± 11.7040.8 ± 12.5442.0 ± 11.7140.9 ± 12.7741.2 ± 12.25
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTDV Lot 1TDV Lot 2TDV Lot 3Total
Female69144150134497
Male63119114130426
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTDV Lot 1TDV Lot 2TDV Lot 3Total
Hispanic or Latino916252070
Not Hispanic or Latino120247239244850
Unknown or Not Reported30003
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTDV Lot 1TDV Lot 2TDV Lot 3Total
American Indian or Alaska Native20024
Asian324312
Native Hawaiian or Other Pacific Islander01012
Black or African American23555644178
White104200202208714
More than one race052613
Unknown or Not Reported00000
Height
Height(cm)PlaceboTDV Lot 1TDV Lot 2TDV Lot 3Total
Mean171.7 ± 10.67171.0 ± 9.68171.6 ± 10.11171.8 ± 9.86171.5 ± 9.99
Weight
Weight(kg)PlaceboTDV Lot 1TDV Lot 2TDV Lot 3Total
Mean82.37 ± 15.27579.63 ± 15.20381.31 ± 16.54382.35 ± 15.92881.28 ± 15.827
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboTDV Lot 1TDV Lot 2TDV Lot 3Total
Mean27.84 ± 3.82527.17 ± 4.27027.50 ± 4.46427.84 ± 4.40827.55 ± 4.309
08

Study locations

14 sites
  • Optimal Research
    Huntsville, Alabama 35802, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92805, United States
  • Advanced Clinical Research
    Boise, Idaho 83704, United States
  • Optimal Research
    Peoria, Illinois 61614, United States
  • Synexus Limited- Council Bluffs
    Council Bluffs, Iowa 51503, United States
  • Heartland Research Associates LLC - Augusta
    Augusta, Kansas 67010, United States
  • Heartland Research Associates LLC
    Park City, Kansas 67219, United States
  • Optimal Research
    Rockville, Maryland 20850, United States
  • Synexus Limited - Minneapolis
    Edina, Minnesota 55435, United States
  • Synexus Limited - St. Louis
    Saint Louis, Missouri 63141, United States
  • Clinical Research Center of Nevada
    Las Vegas, Nevada 89104, United States
  • Synexus Limited - Columbus
    Columbus, Ohio 43212, United States
  • Advanced Clinical Research
    Salt Lake City, Utah 84123, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Aug 2018, 5 months.

Results were first posted in Oct 2020, 2 years 2 months after primary completion. A results delay was requested in Jul 2019.

Of 21 phase 3 interventional studies under Dengue, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2018
First posted
Feb 6, 2018
StartActual
Feb 12, 2018
Primary completionActual
Aug 3, 2018
CompletionActual
Jan 14, 2019
Results delay requested
Jul 11, 2019
Results first posted
Oct 20, 2020
Last update
Oct 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03423173
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 6, 2018
Start date
Feb 12, 2018
Primary completion
Aug 3, 2018
Completion
Jan 14, 2019
Results posted
Oct 20, 2020
Last update
Oct 20, 2020

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion